Article Data

  • Views 464
  • Dowloads 105

Original Research

Open Access

MicroRNA signatures of platinum-resistance in ovarian cancer

  • H-C Ying1,*,
  • H-Y Xu2
  • J. Lv3
  • T-S Ying1
  • Q. Yang1

1Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang, China

2Department of Gynecology and Obstetrics, the Ninth Hospital of Shenyang, Shenyang, China

3Department of Oncology, the Fifth Hospital of Shenyang, Shenyang , China

DOI: 10.12892/ejgo2511.2015 Vol.36,Issue 1,February 2015 pp.16-20

Published: 10 February 2015

*Corresponding Author(s): H-C Ying E-mail: huanchunying@hotmail.com

Abstract

Objectives: The authors utilized a microRNA (miRNA) array to compare the differentially expressed miRNAs in platinum-resistant associated ovarian cancer cells. Materials and Methods: The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). Results: The authors identified that several miRNAs are altered in collected 86 samples of human ovarian cancer cell-lines, with four significantly deregulated miRNAs and 13 upregulated miRNAs. Of which, miR-141-3p was the most differentially expressed miRNA between COC1 group (1.7833 ± 0.7213) and COC1/DDP group (14.0433 ± 4.4895) (p < 0.05). Additionally, the product curve of PCR amplification indicated that miR-141-3p had a significant higher expression level in chemotherapy resistant group (n=20) rather than in chemotherapy sensitive group (n=20) (9.56 ± 1.04 vs. 1.59 ± 0.91, p < 0.05). Conclusions: The present results suggest that miR-141-3p might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response.

Keywords

Ovarian cancer; miRNA; Platinum-resistant; Platinum-based drug; Micoarray.

Cite and Share

H-C Ying,H-Y Xu,J. Lv,T-S Ying,Q. Yang. MicroRNA signatures of platinum-resistance in ovarian cancer . European Journal of Gynaecological Oncology. 2015. 36(1);16-20.

References

[1] Sankaranarayanan R., Ferlay J.: “Worldwide burden of gynaecological cancer: the size of the problem”. Best. Pract. Res. Clin. Obstet. Gynaecol., 2006, 20, 207.

[2] Agarwal R., Kaye S.B.: “”Ovarian cancer: strategies for overcoming resistance to chemotherapy”. Nat. Rev. Cancer, 2003, 3, 502.

[3] Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M.: “Cancer statistics, 2001”. CA Cancer J. Clin., 2001, 51, 15.

[4] Bartel D.P.: “MicroRNAs: genomics, biogenesis, mechanism, and function”. Cell, 2004, 116, 281.

[5] Sevignani C., Calin G.A., Siracusa L.D., Croce C.M.: “Mammalian microRNAs: a small world for fine-tuning gene expression”. Mamm. Genome, 2006, 17, 189.

[6] Bushati N., Cohen S.M.: “”microRNA functions”. Annu. Rev. Cell. Dev. Biol., 2007, 23, 175.

[7] Miller T.E., Ghoshal K., Ramaswamy B., Roy S., Datta J., Shapiro C.L., Jacob S., Majumder S.: “MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1”. J.Biol. Chem., 2008, 283, 29897.

[8] Yang H., Kong W., He L., Zhao J.J., O’Donnell J.D., Wang J., et al.: “MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN”. Cancer Res., 2008, 68, 425.

[9] Eitan R., Kushnir M., Lithwick-Yanai G., David M.B., Hoshen M., Glezerman M., et al.: “Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients”. Gynecol. Oncol., 2009, 114, 253.

[10] Fung-Kee-Fung M., Oliver T., Elit L., Oza A., Hirte H., Bryson P.: “Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr. Oncol., 2007, 14, 195.

[11] Smyth G.K., Michaud J., Scott H.S.: “Use of within-array replicate spots for assessing differential expression in microarray experiments”. Bioinformatics, 2005, 21, 2067.

[12] Livak K.J., Schmittgen T.D.: “Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method”. Methods, 2001, 25, 402.

[13] Taylor D.D., Gercel-Taylor C.: “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer”. Gynecol. Oncol., 2008, 110, 13.

[14] Zhang L., Volinia S., Bonome T., Calin G.A., Greshock J., Yang N., et al.: “Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer”. Proc. Natl. Acad. Sci. U S A, 2008, 105, 7004

[15] Hu X., Macdonald D.M., Huettner P.C., Feng Z., El Naqa I.M., Schwarz J.K., et al.: “A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer”. Gynecol. Oncol., 2009, 114, 457

[16] Calin G.A., Croce C.M.: “MicroRNA signatures in human cancers”. Nat. Rev. Cancer, 2006, 6, 857.

[17] Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al.: “Unique microRNA molecular profiles in lung cancer diagnosis and prognosis”. Cancer Cell, 2006, 9, 189.

[18] Esquela-Kerscher A., Trang P., Wiggins J.F., Patrawala L., Cheng A., Ford L., et al.: “The let-7 microRNA reduces tumor growth in mouse models of lung cancer”. Cell Cycle, 2008, 7, 759.

[19]Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., et al.: “The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1”. Nat. Cell Biol., 2008, 10, 593.

[20] Du Y., Xu Y., Ding L., Yao H., Yu H., Zhou T., Si J.: “Down-regulation of miR-141 in gastric cancer and its involvement in cell growth”. J. Gastroenterol., 2009, 44, 556.

[21] Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., et al.: “microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. U S A, 2006, 103, 9136.

[22] Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., et al.: “MicroRNA expression profiles in serous ovarian carcinoma”. Clin. Cancer Res., 2008, 14, 2690.

[23] Wyman S.K., Parkin R.K., Mitchell P.S., Fritz B.R., O’Briant K., Godwin A.K., et al.: “Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries”. PLoS One, 2009, 4, e5311

[24] Park S.M., Gaur A.B., Lengyel E., Peter M.E.: “The miR-200 family determines the epithelial phenotype of cancer cells by targeting the Ecadherin repressors ZEB1 and ZEB2”. Genes Dev., 2008, 22, 894.

[25] Li L., Li S., Yang Y., Wan X.: “The expression of miRNA-200c in human epithelial ovarian cancer cells and tumor tissues”. J. Second Military Medical University, 2011, 6, 612.

[26] Furnari F.B., Huang H.S., Cavenee W.K.: “The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells”. Cancer Res., 1998, 58, 5002.

[27] Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., et al.: “Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival”. Cancer Res., 2004, 64, 3753.

[28] Van Jaarsveld M., Helleman J., Berns E.M., Wiemer E.A.: “MicroRNAs in ovarian cancer biology and therapy resistance”. Int. J. Biochem. Cell. Biol., 2010, 42, 1282.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top